# Family C C001 Implementation Development Evaluation V1

## Scope

Step 03.03 / Command 05 ran the one preregistered DEVELOPMENT evaluation of
`C1-IMP-001`, `C001_COMPRESSION_PRIORITY_CAPACITY_RANKING_V1`. The primary
mode was `EXECUTABLE_INTEGER_SHARE_500K` over 2022-01-01 through 2024-12-31.
Validation was not accessed and Strategy V2 was not created.

The frozen C001 evidence remained the motivation rather than a new signal
claim: the compression-pass event cohort had `CLEAR_POSITIVE` attribution,
while the original breakout-strength capacity ranking was
`NO_DISCRIMINATION` and selected worse events. This command tested whether a
compression-priority admission order could preserve more of that existing
signal edge.

## Freeze gate and exact one-change method

All preregistered inputs passed before performance:

- implementation config: `d9de8dbbf0e288066565fcf9a4ef2b4cd494ed3f07760529298669226a119662`
- parameter hash: `6a5b49423e3fb30c708c9e1ae6a7cf5a5c0cf7306666d4f35f7428123d36915c`
- preregistration hash: `a5939b4d11282d0c8e40a2e1d9cebde79d8b62bf5d4a315adfcb8f853c366c7a`
- success-criteria hash: `90365ad9e45328a918bb714e03df78dfc049c0e335e9c6893216594c690978c0`
- signal-set hash: `096a11a85a72138176fb02b28efec52030e00c819c1bc67bca6fd8ae41abce9f`
- C001 attribution hash: `26a320930facd5c3007a75e22573e27171d6e85cb6a4ea02dc209e6975a38e4b`
- frozen BRK-C-001 result: `8adc1aec00041256748a8fa086b4dae562a6841b844875fc39b3dd19b61680e4`

The rebuilt treatment signal set exactly matched all 4,247 frozen complete-path
C001 signals: missing 0, extra 0, and field mismatches 0.

The control ranking remained breakout strength descending, then symbol
ascending. The treatment ranking was exactly compression range ascending,
breakout strength descending, then symbol ascending. This same-day ordering
was the only experimental change. The 20-session breakout, 10-session
compression at or below 8%, ₹500,000 capital, 20-position cap, 5% current
equity sizing, whole shares, one-position-per-symbol rule, T+1 open entry,
10-completed-session hold, next-open exit, frozen costs, and absence of stops
and targets were unchanged.

## Treatment portfolio result

The treatment finished at ₹503,077.3245 net from ₹500,000, a net return of
0.6154649% and net CAGR of 0.2047355%. Gross ending equity was ₹609,536.8045.
Max drawdown was 19.1468901%, annualized volatility 11.1333726%, and the
Sharpe-like metric 0.0746276.

There were 1,167 closed positions, a 49.2716367% position win rate, net
expectancy of 0.0484116%, and net PF of 1.0049999. Average winner was
4.6346362%, average loser -4.4061139%, and median position return -0.1038409%.
Turnover was 108.8203647x, modeled costs were ₹106,459.48, average cash was
₹117,164.58, and average concurrent positions were 15.7066.

Yearly net returns were -6.7164772% in 2022, +2.4195801% in 2023, and
+5.3117448% in 2024.

## Capacity and event quality

Of 4,247 valid pre-capacity signals, 1,167 were admitted, 2,329 were rejected
for capacity, 697 were rejected because the symbol was already open, and 54
were unaffordable under whole-share cash accounting. The capacity-rejection
rate was 54.8387097%. This lower rejection count is not treated as success;
the ranking changed future occupancy paths while the signal set and 20-slot
capacity remained fixed.

Treatment admitted-event quality was:

- win rate: 49.3573265% versus frozen 49.8290598%; threshold 52.8290598% — FAIL
- normalized expectancy: 0.0536756% versus frozen 0.2132077%; threshold 0.2451889% — FAIL
- normalized PF: 1.0240407 versus frozen 1.0897956; threshold 1.1397956 — FAIL

Treatment capacity-rejected events retained stronger quality: 52.1253757%
win rate, 0.7466028% normalized expectancy, and PF 1.3615480.

## Admission replacement diagnostics

The old and new admitted sets intersected on 761 events. There were 409
old-only admissions and 406 new-only admissions, giving a Jaccard similarity
of 0.4828680 and 815 changed admission memberships.

Old-only events had a 53.5452323% win rate, 0.6623968% expectancy, PF
1.2847938, and 0.5157908% median return. New-only events had a 52.2167488%
win rate, 0.2071591% expectancy, PF 1.1079903, and 0.3246692% median return.
All four differences favored the old-only cohort, so
`COMPRESSION_PRIORITY_REPLACEMENT_QUALITY = WORSE`.

The pooled same-formation-date diagnostic produced new-minus-old differences
of -1.3284835 percentage points in win rate, -0.1911216 percentage points in
median return, -0.4552377 percentage points in expectancy, and -0.1768034 in
PF. This matched analysis is diagnostic only.

## Frozen criteria A–H

- A `CAPACITY_QUALITY_IMPROVEMENT`: FAIL
- B `PORTFOLIO_PROFITABILITY`: FAIL
- C `RETURN_NON_DEGRADATION`: FAIL
- D `DRAWDOWN_NON_DEGRADATION`: PASS
- E `TEMPORAL_SUPPORT`: PASS
- F `COST_NON_DEGRADATION`: PASS
- G `SAMPLE_ADEQUACY`: PASS
- H `ACCOUNTING_DATA_INTEGRITY`: PASS

Five of eight criteria passed. There was no fatal mechanics, accounting, or
sample failure, but all three admitted-quality dimensions were worse than the
frozen reference and no quality threshold passed. Under the preregistered
decision rules:

`C1_IMP_001_DEVELOPMENT_RESULT = FAILED`

`FAMILY_C_C001_POST_IMPLEMENTATION_STAGE = CLOSE_IMPLEMENTATION_HYPOTHESIS`

## Governance and limitations

No parameter was retuned after observing the result. No second ranking,
alternative compression threshold, capacity, sizing, holding period, stop,
target, volume condition, or gap condition was tested. The Command 04
preregistration remains unchanged; the development registry records
`DEVELOPMENT_EVALUATED` with its original parameter and preregistration hashes.

The evidence is DEVELOPMENT-only and does not establish out-of-sample
performance. Event-quality comparisons use the frozen normalized fixed-notional
attribution method, while portfolio metrics use executable whole-share
accounting. No validation data, live signals, orders, broker calls, database
writes, migrations, or Supabase persistence were used.
